Beta Bionics, Inc. (NASDAQ: BBNX) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.51 | Insider Own | 2.94% | Shs Outstand | 44.99M | Perf Week | -19.05% |
| Market Cap | 577.22M | Forward P/E | - | EPS next Y | -2.16 | Insider Trans | -5.74% | Shs Float | 19.80M | Perf Month | -23.17% |
| Enterprise Value | 539.41M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 14.69% | Perf Quarter | 25.78% |
| Income | -73.71M | P/S | 4.85 | EPS this Y | -42.32% | Inst Trans | - | Short Ratio | 6.72 | Perf Half Y | -13.25% |
| Sales | 119.01M | P/B | 2.23 | EPS next Y | -0.60% | ROA | -24.96% | Short Interest | 6.61M | Perf YTD | -57.89% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -26.30% | 52W High | 34.04 -60.78% | Perf Year | -23.45% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -30.98% | 52W Low | 9.16 45.80% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 58.31% | Volatility | 9.17% 7.18% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 4.53 | EPS Y/Y TTM | 82.44% | Oper. Margin | -69.75% | ATR (14) | 1.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.96 | Sales Y/Y TTM | 69.23% | Profit Margin | -61.32% | RSI (14) | 29.54 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.88 | EPS Q/Q | 5.77% | SMA20 | -21.29% | Beta | 1.18 | Target Price | 19.83 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | 55.56% | SMA50 | -13.25% | Rel Volume | 2.04 | Prev Close | 12.83 |
| Employees | 423 | LT Debt/Eq | 0.02 | Earnings | Oct 27 | SMA200 | -26.97% | Avg Volume | 981.24K | Price | 13.35 |
| IPO Date | Jan 30, 2025 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.53% 2.52% | Net Debt/EBITDA | 0.53 | Volume | 2,004,576 | Change | 4.05% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Resumed | UBS | Buy | $24 → $22 |
| Jul-15-26 | Reiterated | Goldman Sachs | Buy | $17 → $19 |
| Jul-13-26 | Reiterated | Truist Securities | Buy | $25 → $22 |
| May-27-26 | Reiterated | Goldman Sachs | Buy | $25 → $17 |
| Feb-18-26 | Reiterated | Lake Street | Buy | $40 → $20 |
| Feb-18-26 | Reiterated | Robert W. Baird | $28 → $14 | |
| Feb-18-26 | Reiterated | Stifel Nicolaus | $25 → $22 | |
| Feb-08-26 | Initiated | UBS | Buy | $24 |
| Feb-04-26 | Reiterated | Stifel Nicolaus | $31 → $25 | |
| Feb-02-26 | Reiterated | Truist Securities | Buy | $37 → $25 |
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|---|
| Total Revenue | 119 | 100 | 65 | 12 | 0 | |
| Cost of Goods Sold Incl. D&A | 49 | 45 | 29 | 6 | 0 | |
| Gross Profit | 69 | 56 | 36 | 6 | 0 | |
| Selling, General and Administrative Excl. Other | 113 | 92 | 55 | 24 | 33 | |
| Research and Development | 38 | 35 | 26 | 18 | 31 | |
| Other Operating Expense | 1 | 0 | 0 | 0 | 2 | |
| Operating Income | -83 | -72 | -45 | -36 | -66 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | |
| Non-Operating Income (Expense) | 10 | -2 | -10 | -8 | 1 | |
| Net Income Before Taxes | -72 | -73 | -55 | -44 | -65 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -72 | -73 | -55 | -44 | -65 | |
| Net Income From Continuing Operations | -72 | -73 | -55 | -44 | -65 | |
| Net Income | -72 | -73 | -55 | -44 | -65 | |
| EPS (Recurring) | -1.65 | -1.81 | -8.60 | -8.31 | -12.96 | |
| EPS (Basic, Before Extraordinaries) | -1.65 | -1.81 | -8.60 | -8.31 | -12.96 | |
| EPS (Diluted) | -1.65 | -1.81 | -8.60 | -8.31 | -12.96 | |
| EBITDA | -72 | -70 | -54 | -43 | -63 | |
| Other After Tax Adjustments | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | |
| Price To Sales Ratio | 5.05 | 12.49 | — | — | — | |
| Gross Margin | 57.98 | 56.00 | 55.38 | 50.00 | — | |
| Operating Margin | -69.75 | -72.00 | -69.23 | -300.00 | — | |
| Net Margin | -60.50 | -73.00 | -84.62 | -366.67 | — | |
| Shares Outstanding | 45 | 41 | 6 | 5 | 5 | |
| Market Capitalization | 601 | 1,249 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Feider Stephen | Chief Financial Officer | Jun 29 '26 | Sale | 17.03 | 9,792 | 166,762 | 165,931 | Jul 02 |
| Feider Stephen | Chief Financial Officer | Jun 29 '26 | Option Exercise | 5.10 | 9,792 | 49,940 | 170,949 | Jul 02 |
| Feider Stephen | Chief Financial Officer | Jun 26 '26 | Option Exercise | 5.10 | 10,086 | 51,438 | 171,157 | Jul 02 |
| Feider Stephen | Chief Financial Officer | Jun 26 '26 | Sale | 17.05 | 10,208 | 174,012 | 165,931 | Jul 02 |
| Hopman Mark | Chief Commercial Officer | Jun 24 '26 | Sale | 15.01 | 1,258 | 18,880 | 129,354 | Jun 25 |
| Jones Christy | Director | Jun 24 '26 | Sale | 15.00 | 1,406 | 21,090 | 25,994 | Jun 25 |
| Hopman Mark | Chief Commercial Officer | Jun 04 '26 | Sale | 12.31 | 275 | 3,385 | 130,612 | Jun 05 |
| Jones Christy | Director | Jun 04 '26 | Sale | 14.00 | 2,811 | 39,354 | 27,400 | Jun 05 |
| Hopman Mark | Chief Commercial Officer | Jun 02 '26 | Sale | 12.61 | 5,329 | 67,183 | 130,887 | Jun 03 |
| Mensinger Mike | Chief Product Officer | Jun 02 '26 | Sale | 12.61 | 4,378 | 55,194 | 184,415 | Jun 03 |
| Russell Steven Jon | Chief Medical Officer | Jun 02 '26 | Sale | 12.61 | 4,222 | 53,227 | 173,849 | Jun 03 |
| Feider Stephen | Chief Financial Officer | Jun 02 '26 | Sale | 12.61 | 6,676 | 84,165 | 166,053 | Jun 03 |
| Saint Sean | President & CEO | Jun 02 '26 | Sale | 12.61 | 16,872 | 212,707 | 420,937 | Jun 03 |
| Lezack Adam | Director | May 22 '26 | Sale | 11.21 | 998 | 11,188 | 27,399 | May 26 |
| Jones Christy | Director | May 21 '26 | Sale | 9.95 | 1,998 | 19,880 | 13,246 | May 26 |